Home » Galera Therapeutics Doses First Patient in Phase 2 Trial of Avasopasem Manganese for COVID-19
Galera Therapeutics Doses First Patient in Phase 2 Trial of Avasopasem Manganese for COVID-19
Galera Therapeutics has dosed the first patient in a phase 2 clinical trial of avasopasem manganese (GC4419) for the treatment of critically ill COVID-19 patients.
The trial will evaluate the safety and efficacy of the drug compared to a placebo for improving 28-day mortality in up to 50 hospitalized adults, who will either receive a 90-mg dose of the treatment or a placebo by infusion twice daily for seven days.
Avasopasem manganese is currently under development for radiation-induced severe oral mucositis, a common side effect of chemotherapy.
Upcoming Events
-
07May
-
14May
-
30May